<DOC>
	<DOCNO>NCT00295503</DOCNO>
	<brief_summary>To estimate time progression cancer patient previously untreated mesothelioma receive cisplatin , pemetrexed bevacizumab</brief_summary>
	<brief_title>Cisplatin , Pemetrexed Bevacizumab Untreated Malignant Mesothelioma</brief_title>
	<detailed_description>Secondary endpoint include : objective response rate overall survival In addition , objective analysis correlative science data determine association tumor expression VEGF/KDR complex and/or presence sv40 ( detect PCR amplification ) objective response .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Inclusion criterion 5.2.1 Patients must histologically prove malignant mesothelioma ( epithelial , sarcomatoid , mixed subtype ) amenable curative surgery radiotherapy . Eligible site origin include pleura , peritoneum , tunica vaginalis . 5.2.2 Patient 's disease must amenable curative treatment surgery . Evidence gross unresectability include limited direct extension chest wall , mediastinal hilar lymphadenopathy , pulmonary cardiac function inadequate tolerate resection , sarcomatoid mixed histology . 5.2.3 Patients must &gt; 18 year old 5.2.4 Patients must measurable disease . Adequate organ function functional status . General Medical Concerns 5.3.1 Patients must pregnant breast feeding . 5.3.2 No `` currently active '' second malignancy nonmelanoma skin cancer . Patients consider `` currently active '' second malignancy complete therapy le 30 % risk relapse . 5.3.3 No uncontrolled intercurrent illness include limited : active infection , symptomatic congestive heart failure , unstable angina , cardiac arrhythmia , psychiatric/social situation would limit compliance study requirement . 5.3.4 No HIV positive patient receive combination antiretroviral therapy possible pharmacokinetic interaction study medication . 5.3.5 History allergic reaction attribute compound similar chemical biologic composition bevacizumab agent use study . 5.3.6 Inability interrupt aspirin nonsteroidal medication 5 day period . c. BevacizumabSpecific Concerns Subjects meeting follow criterion ineligible study entry : 5.3.7 Patients brain metastasis exclude 5.3.8 History myocardial infarction CVA ( stroke ) within 6 month study entry . 5.3.9 Evidence bleed diathesis coagulopathy . Patients therapeutic dos coumadin eligible long INR maintain range 23 evidence active bleeding . 5.3.10 Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study 5.3.11 Urine protein : creatinine ratio le 1.0 screen 5.3.12 Serious , nonhealing wound , ulcer , bone fracture</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>mesothelioma</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>chemotherapy</keyword>
</DOC>